Grace O’nEill
Research Subjects
Research Interests
Grace O’nEill has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Cynthia J Willey
Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island , Kingston, RI
1 shared publication Dominik Naessens
Janssen Pharmaceutica NV , Beerse
1 shared publication- James Kershaw
Adelphi Real World , Bollington
1 shared publication - Myrlene Sanon
Johnson & Johnson Horsham Pennsylvania USA
1 shared publication - Sophie Barlow
Adelphi Real World, Bollington, UK
1 shared publication Sumesh Kachroo
Janssen Scientific Affairs, LLC , Horsham, PA
1 shared publication
Latest Publications
- Open Access
- 29 November 2024
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 7 (1) , otae074
Real-World Impact of Uncontrolled Symptoms and Suboptimal Treatment Response in Patients With Crohn’s Disease in the United States and Europe
Background: Despite a wide range of available treatments, there is limited evidence as to why significant numbers of Crohn’s disease (CD) patients do not achieve disease remission or continue to have residual symptom burden. We aimed to quantify the impact of this suboptimal treatment on patient symptom incidence and severity, quality of life (QoL), and work impairment. Methods: Data were derived from the Adelphi Real World CD Disease Specific Programme, a cross-sectional survey of CD patients and their treating physicians in France, Germany, Italy, Spain, the United Kingdom, and the United States between January 2020 and March 2021. Physicians reported on patients’ clinical history, disease status, symptom load, and treatment. Patients reported their QoL and activity impairment using the EQ-5D-5L and Work Productivity and Activity Impairment measures. Patients were divided into remitters, partial remitters, and non-remitters. Multivariate regression models were used to assess the impact of remission status on clinical and QoL outcomes. Results: Of 1786 patients, 24.1% were remitters, 53.2% were partial remitters, and 22.7% were non-remitters. Partial remitters and non-remitters had a significantly higher symptom load than remitters (P < .05), and non-remitters were up to 15 times more likely to experience key symptoms than remitters. Both non-remitters and partial remitters were also significantly more likely to have increased symptom severity (P < .05). Non-remitters were more likely to have switched treatment and received more treatment lines, as well as having significantly worse QoL, than remitters. Conclusions: Suboptimal treatment response was associated with increased symptoms and QoL burden. Despite the increased burden experienced, partial remitters were not more likely to switch or receive more treatment lines than remitters, demonstrating the need to initiate effective therapy.
- 29 November 2024
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 7 (1) , otae074
Open AccessReal-World Impact of Uncontrolled Symptoms and Suboptimal Treatment Response in Patients With Crohn’s Disease in the United States and Europe
Background: Despite a wide range of available treatments, there is limited evidence as to why significant numbers of Crohn’s disease (CD) patients do not achieve disease remission or continue to have residual symptom burden. We aimed to quantify the impact of this suboptimal treatment on patient symptom incidence and severity, quality of life (QoL), and work impairment. Methods: Data were derived from the Adelphi Real World CD Disease Specific Programme, a cross-sectional survey of CD patients and their treating physicians in France, Germany, Italy, Spain, the United Kingdom, and the United States between January 2020 and March 2021. Physicians reported on patients’ clinical history, disease status, symptom load, and treatment. Patients reported their QoL and activity impairment using the EQ-5D-5L and Work Productivity and Activity Impairment measures. Patients were divided into remitters, partial remitters, and non-remitters. Multivariate regression models were used to assess the impact of remission status on clinical and QoL outcomes. Results: Of 1786 patients, 24.1% were remitters, 53.2% were partial remitters, and 22.7% were non-remitters. Partial remitters and non-remitters had a significantly higher symptom load than remitters (P < .05), and non-remitters were up to 15 times more likely to experience key symptoms than remitters. Both non-remitters and partial remitters were also significantly more likely to have increased symptom severity (P < .05). Non-remitters were more likely to have switched treatment and received more treatment lines, as well as having significantly worse QoL, than remitters. Conclusions: Suboptimal treatment response was associated with increased symptoms and QoL burden. Despite the increased burden experienced, partial remitters were not more likely to switch or receive more treatment lines than remitters, demonstrating the need to initiate effective therapy.